Read on Twitter
Having #obesity and its associated diseases is “Big Business” and GLP-1 agonists will effect profits
The “Ozempic effect” is coming for kidney drugs, heart-disease treatments, and more - these drugs may effect the production use and profits of other drugs- @Bloomberg @business 1/
The “Ozempic effect” is coming for kidney drugs, heart-disease treatments, and more - these drugs may effect the production use and profits of other drugs- @Bloomberg @business 1/
The insanity of the public concern is that these medications could negatively effect the economy.
The reality is that these medications could reduce obesity rates and improve the health of people with 229 associated conditions. 2/
The reality is that these medications could reduce obesity rates and improve the health of people with 229 associated conditions. 2/
Improving the health of patients with #obesity will have a positive effect on the economy by reducing the cost of employer insurance, reducing sick time, improving productivity, and especially improving the quality of life. Where is the negativity? 3/
The cost of #obesity medications is egregious but there is a hope as new medications become available, competition between pharmaceutical companies and the less effective and desirable GLP-1 agonists will drive the market down. 4/
• • •
Missing some Tweet in this thread? You can try to
force a refresh
